Overexpression of the proviral integration site for Moloney murine leukemia virus (PIM) kinase 1 (PIM1) has emerged as a pivotal factor in multiple myeloma (MM) progression, positioning PIM1 as a promising target for novel therapeutic interventions. In response, this study developed a robust virtual screening protocol that integrates deep learning-based drug screening with docking-based approaches to systematically identify potential PIM1 inhibitors. This strategy led to the identification of a compound with potent inhibitory activity against PIM1, evidenced by an IC50 of 307 nM in a homogeneous time-resolved fluorescence (HTRF) bioassay. Moreover, compound 1 effectively suppressed the proliferation of MM.1S and NCI-H929 cells. Detailed molecular dynamics simulations further elucidated the binding interactions between the compound and PIM1, offering critical insights into its mechanism of action.
Lu et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: